Treatment of Lupus Tumidus in the Absence of Severe or Disseminated Cutaneous Lupus Erythematosus Skin Lesions
When lupus tumidus presents with circumscribed skin lesions — without evidence of severe or disseminated cutaneous lupus erythematosus — a localised treatment strategy directed at the affected skin is appropriate. The full protocol defines the specific agents, their selection, and how duration should be managed.
Clinical Scenario
This protocol applies in the absence of severe or disseminated cutaneous lupus erythematosus skin lesions. Lesions are circumscribed and amenable to targeted topical treatment, rather than requiring systemic management.
Treatment Approach — Partial Summary
Management focuses on topical agents applied directly to skin lesions, with particular attention to limiting the duration of use to the shortest time necessary.
Full agent selection, alternatives, and clinical guidance are available in the complete protocol.
References
DOI: 10.1111/ddg.14491
- Topical glucocorticoids are recommended for treating circumscribed CLE lesions.
- Class 2-4 topical glucocorticoids are the treatment of choice for cutaneous lupus erythematosus (CLE).
- Considering the side effect profile of topical glucocorticoids and the location of the skin lesions, it is recommended to limit the duration of use to the shortest possible time.
- Topical calcineurin inhibitors are recommended predominantly for treating facial lesions, but also as an alternative to topical glucocorticoids.
- Tacrolimus 0.1 % ointment was most effective in patients with lupus erythematosus tumidus (LET), followed by SCLE patients.
View source ↗